BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 33187551)

  • 1. Identification of a novel subpopulation of Caspase-4 positive non-small cell lung Cancer patients.
    Terlizzi M; Colarusso C; De Rosa I; Somma P; Curcio C; Aquino RP; Panico L; Salvi R; Zito Marino F; Botti G; Pinto A; Sorrentino R
    J Exp Clin Cancer Res; 2020 Nov; 39(1):242. PubMed ID: 33187551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MYC expression correlates with PD-L1 expression in non-small cell lung cancer.
    Kim EY; Kim A; Kim SK; Chang YS
    Lung Cancer; 2017 Aug; 110():63-67. PubMed ID: 28676221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer.
    Belmont L; Rabbe N; Antoine M; Cathelin D; Guignabert C; Kurie J; Cadranel J; Wislez M
    Int J Cancer; 2014 Feb; 134(4):765-77. PubMed ID: 23913633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.
    Riccardo F; Arigoni M; Buson G; Zago E; Iezzi M; Longo D; Carrara M; Fiore A; Nuzzo S; Bicciato S; Nanni P; Landuzzi L; Cavallo F; Calogero R; Quaglino E
    BMC Genomics; 2014; 15 Suppl 3(Suppl 3):S1. PubMed ID: 25077564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 6. Expression and clinical significance of PD-L1 and c-Myc in non-small cell lung cancer.
    Zhou C; Che G; Zheng X; Qiu J; Xie Z; Cong Y; Pei X; Zhang H; Sun H; Ma H
    J Cancer Res Clin Oncol; 2019 Nov; 145(11):2663-2674. PubMed ID: 31541338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women.
    Nelson HH; Christiani DC; Mark EJ; Wiencke JK; Wain JC; Kelsey KT
    J Natl Cancer Inst; 1999 Dec; 91(23):2032-8. PubMed ID: 10580029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis.
    Meng D; Yuan M; Li X; Chen L; Yang J; Zhao X; Ma W; Xin J
    Lung Cancer; 2013 Jul; 81(1):1-10. PubMed ID: 23608713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-myc/miR-150/EPG5 axis mediated dysfunction of autophagy promotes development of non-small cell lung cancer.
    Li H; Liu J; Cao W; Xiao X; Liang L; Liu-Smith F; Wang W; Liu H; Zhou P; Ouyang R; Yuan Z; Liu J; Ye M; Zhang B
    Theranostics; 2019; 9(18):5134-5148. PubMed ID: 31410206
    [No Abstract]   [Full Text] [Related]  

  • 11. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
    Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
    Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of surviving gene and its relationship with expression of P53, c-myc, k-ras proteins in non-small-cell lung cancer].
    Wang X; Chen S; Zhang Z
    Zhonghua Jie He He Hu Xi Za Zhi; 2001 Jun; 24(6):371-4. PubMed ID: 11802993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel molecular staging protocol for non-small cell lung cancer.
    Miyake M; Adachi M; Huang C; Higashiyama M; Kodama K; Taki T
    Oncogene; 1999 Apr; 18(14):2397-404. PubMed ID: 10327061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The expression of programmed death receptor 1 in non-small cell lung cancer and its clinicopathological features and prognosis showed a connection with epidermal growth factor receptor gene mutations].
    Yin H; Liao CG; Wang YQ; Li Z; Fan LL; Qian ML; Lu N
    Zhonghua Zhong Liu Za Zhi; 2017 Jun; 39(6):419-423. PubMed ID: 28635230
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer.
    Graziano SL; Gamble GP; Newman NB; Abbott LZ; Rooney M; Mookherjee S; Lamb ML; Kohman LJ; Poiesz BJ
    J Clin Oncol; 1999 Feb; 17(2):668-75. PubMed ID: 10080613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations of p53 and K-ras genes as prognostic factors for non-small cell lung cancer.
    Huang CL; Taki T; Adachi M; Konishi T; Higashiyama M; Kinoshita M; Hadama T; Miyake M
    Int J Oncol; 1998 Mar; 12(3):553-63. PubMed ID: 9472092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.
    Cooper WA; Tran T; Vilain RE; Madore J; Selinger CI; Kohonen-Corish M; Yip P; Yu B; O'Toole SA; McCaughan BC; Yearley JH; Horvath LG; Kao S; Boyer M; Scolyer RA
    Lung Cancer; 2015 Aug; 89(2):181-8. PubMed ID: 26024796
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer.
    Sepesi B; Nelson DB; Mitchell KG; Gibbons DL; Heymach JV; Vaporciyan AA; Swisher SG; Roszik J
    Ann Thorac Surg; 2018 Jun; 105(6):1621-1626. PubMed ID: 29510096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Skp2 gene copy number aberrations are common in non-small cell lung carcinoma, and its overexpression in tumors with ras mutation is a poor prognostic marker.
    Zhu CQ; Blackhall FH; Pintilie M; Iyengar P; Liu N; Ho J; Chomiak T; Lau D; Winton T; Shepherd FA; Tsao MS
    Clin Cancer Res; 2004 Mar; 10(6):1984-91. PubMed ID: 15041716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung.
    Nemunaitis J; Klemow S; Tong A; Courtney A; Johnston W; Mack M; Taylor W; Solano M; Stone M; Mallams J; Mues G
    Am J Clin Oncol; 1998 Apr; 21(2):155-60. PubMed ID: 9537203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.